Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, pl...

Por Ratner, R E, Rosenstock, J, Boka, G
Publicado em 2010

Yale studies in ambulatory medical care. V. Determinants of use of hospital emergency services.

Por Weinerman, E R, Ratner, R S, Robbins, A, Lavenhar, M A
Publicado em 1966

Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomize...

Por Ratner, R, Wynne, A, Nakhle, S, Brusco, O, Vlajnic, A, Rendell, M
Publicado em 2011

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled...

Por Ratner, R, Nauck, M, Kapitza, C, Asnaghi, V, Boldrin, M, Balena, R
Publicado em 2010

Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase...

Por Freemantle, N, Meneghini, L, Christensen, T, Wolden, M L, Jendle, J, Ratner, R
Publicado em 2013

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiri...

Por Garber, A, Henry, R R, Ratner, R, Hale, P, Chang, C T, Bode, B
Publicado em 2011

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

Por Ratner, R E, Gough, S C L, Mathieu, C, Del Prato, S, Bode, B, Mersebach, H, Endahl, L, Zinman, B
Publicado em 2013

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes

Por Home, P D, Meneghini, L, Wendisch, U, Ratner, R E, Johansen, T, Christensen, T E, Jendle, J, Roberts, A P, Birkeland, K I
Publicado em 2012

Confirming Glycemic Status in the Diabetes Prevention Program: Implications for Diagnosing Diabetes in High Risk Adults

Por Christophi, C. A., Resnick, H. E., Ratner, R. E., Temprosa, M., Fowler, S., Knowler, W. C., Shamoon, H., Barrett-Connor, E., Kahn, S. E.
Publicado em 2012

Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study

Por Orchard, T. J., Temprosa, M., Barrett-Connor, E., Fowler, S., Goldberg, R., Mather, K., Marcovina, S., Montez, M., Ratner, R., Saudek, C., Sherif, H., Watson, K.
Publicado em 2013

The Effect of Lifestyle Intervention and Metformin on Preventing or Delaying Diabetes Among Women With and Without Gestational Diabetes: The Diabetes Prevention Program Outcomes St...

Por Aroda, V. R., Christophi, C. A., Edelstein, S. L., Zhang, P., Herman, W. H., Barrett-Connor, E., Delahanty, L. M., Montez, M. G., Ackermann, R. T., Zhuo, X., Knowler, W. C., Ratner, R. E.
Publicado no J Clin Endocrinol Metab (2015)